Questionable long-term benefit of initial temozolomide monotherapy in IDH-mutant astrocytomas grade 2 and 3

MLA

Weller, J., et al. Questionable Long-Term Benefit of Initial Temozolomide Monotherapy in IDH-Mutant Astrocytomas Grade 2 and 3. May 2022. EBSCOhost, https://doi.org/10.3205/22dgnc132.

APA

Weller, J., Katzendobler, S., Quach, S., Becker, H., Thiele, F., Dorostkar, M., Suchorska, B., Thon, N., & Tonn, J. (2022). Questionable long-term benefit of initial temozolomide monotherapy in IDH-mutant astrocytomas grade 2 and 3. https://doi.org/10.3205/22dgnc132

Chicago

Weller, J, S Katzendobler, S Quach, H Becker, F Thiele, M Dorostkar, B Suchorska, N Thon, and Jc Tonn. 2022. “Questionable Long-Term Benefit of Initial Temozolomide Monotherapy in IDH-Mutant Astrocytomas Grade 2 and 3,” May. doi:10.3205/22dgnc132.